Reviewing Orion Oyj (OTCMKTS:ORINY) & SSP Group (OTCMKTS:SSPPF)

SSP Group (OTCMKTS:SSPPF) and Orion Oyj (OTCMKTS:ORINY) are both retail/wholesale companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Volatility & Risk

SSP Group has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Orion Oyj has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500.

Profitability

This table compares SSP Group and Orion Oyj’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SSP Group	N/A	N/A	N/A
Orion Oyj	23.01%	41.41%	22.43%

Valuation and Earnings

This table compares SSP Group and Orion Oyj”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SSP Group	$4.35 billion	0.26	$9.94 million	N/A	N/A
Orion Oyj	$1.29 billion	4.81	$234.64 million	$1.26	17.42

Orion Oyj has lower revenue, but higher earnings than SSP Group.

Analyst Recommendations

This is a summary of current recommendations and price targets for SSP Group and Orion Oyj, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SSP Group	0	1	0	2	3.33
Orion Oyj	0	0	0	0	0.00

Summary

Orion Oyj beats SSP Group on 5 of the 9 factors compared between the two stocks.

About SSP Group

SSP Group plc operates food and beverage outlets in North America, Europe, the United Kingdom, Ireland, the Asia Pacific, Eastern Europe, the Middle East, and internationally. The company operates outlets at airports, railway stations, motorway service areas, hospitals, and shopping centers. It also operates sandwich shops, cafes, bars, and restaurants. SSP Group plc was founded in 1961 and is headquartered in London, the United Kingdom.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.